Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio, Cure Forward Partner to Improve Patient Access to Genomic Testing Data

NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced a partnership with Cure Forward, a company that aims to provide patients greater access to their genomic test results. 

The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples. The test aids clinicians in choosing optimal therapies for their patients and can accelerate patient enrollment in clinical trials. 

Patients enrolled in Cure Forward and tested with ClearID will have direct access to their data. The test must be ordered by a physician. 

"The barriers to personalized medicine are too high for too many patients," Cure Forward CEO Martin Naley said in a statement. "We help people find innovative testing options like the ClearID test from Cynvenio and then use those results to be more effective champions of their own care." 

Cure Forward is newly formed and also forged a partnership with Paradigm.

Cynvenio announced on Wednesday it raised $25.5 million in a Series B financing round.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.